Tagged with Janssen

Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…

South Africa With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African firm Aspen Pharmacare EUR 600 million (USD 712 million) with the aim of increasing vaccine manufacturing know how across the…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Turkey Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles in Germany, Belgium, France and the US. She explains how Janssen Turkey’s vision “We are here for the better” is…

Switzerland Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies’ global healthcare businesses. Michael Hübner, Early Innovation Partnering Lead and member of the Swiss Johnson & Johnson Leadership Team discusses how they support breakthrough early innovation…

Singapore J&J Singapore’s Guillermo Frydman outlines how his affiliate negotiated the COVID-19 pandemic; why managing J&J’s pharma, medical devices, vision care and consumer businesses together offers unique opportunities to engage as a ‘broad healthcare company’; and Singapore’s role as an innovation hub for the region.   There are many learnings on…

Europe Janssen’s Cyril Titeux highlights the commonalities and challenges within his 31-country portfolio, his hopes and expectations for the evolution of market access in the region, and some of the key industry trends emerging from the COVID-19 pandemic.   I foresee a renewed and increased focus on prevention [post-COVID], especially for…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Norway Equality has long been a deeply held ideal in Norway, where the concept of allemannsretten – the legal right to roam – permeates all aspects of society. Notably, surplus wealth produced by Norway’s sizeable petroleum industry is deposited into the Government Pension Fund Global, today the world’s largest sovereign wealth…

Europe While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as well as develop diagnostics, treatments, and vaccines for COVID-19. Recruitment also continued apace; here four recent country manager appointees share…

Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…

Global Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to the global community on vaccines.   We need to be sure we are not complacent. We have to keep an…